| 摘要: |
| ［摘要］目的 探讨沙利度胺联合吉非替尼新辅助化疗治疗非小细胞肺癌（non small cell lung cancer，NSCLC）的疗效及应用价值，为临床治疗NSCLC提供相应依据．方法 收集2011年1月至2013年1月在汉川市人民医院收治的160例NSCLC患者作为研究对象．随机分为对照组80例和观察组80例，对照组给予直接手术治疗；观察组给予术前沙利度胺联合吉非替尼新辅助化疗与手术治疗．比较2组NSCLC患者近期疗效、6个月及1 a生存率，统计新辅助化疗患者毒副反应发生情况．结果 对照组80例UAP患者，治疗有效率为50.0%；观察组80例，治疗有效率为80%，显著高于对照组，差异有统计学意义（P＜0.05）．观察组患者6个月生存率与1 a生存率分别高达97.5%、92.5%，均显著高于对照组患者87.5%、77.5%，差异有统计学意义（P＜0.05）．观察组患者白细胞减少、关节痛及脱发重度毒副反应发生率较高，而血红蛋白减少、血小板减少、关节痛、恶心呕吐、皮疹及肝功能异常等毒副反应较轻．结论 沙利度胺联合吉非替尼新辅助化疗治疗NSCLC可获得显著疗效，提高患者生存率，毒副反应较轻，值得在临床上进一步深入探讨研究与推广应用． |
| 关键词: ［关键词］沙利度胺 吉非替尼 新辅助化疗 NSCLC |
| DOI： |
| 分类号: |
| 基金项目:［基金项目］国家自然科学基金资助项目（81273647） |
|
| Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer |
|
XU Xiao－hong1,2
|
|
1.（1）Dept. of Pneumology，Pepole’s Hospital of Hanchuan City/ Hanchuan Hospital of Pepole’s Hospital Affiliated to Wuhan University，Hanchuan Wuhan 431600;2）Dept. of Pharmacy，Fujian Provincial Hospital，Fuzhou Fujian 350001，China）
|
| Abstract: |
| ［Abstract］Objective To investigate the clinical effect of preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for non-small cell lung cancer （NSCLC） patients and provide clinical basis for NSCLC therapy. Methods From 2011/1 to 2013/1，we collected 160 NSCLC cases in our hospital and divided them into 2 groups randomly，80 cases in control group and 80 cases in observation group. The patients in the control group were treated with conventional surgical treatment and patients in the observation group were treated with preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib before surgery. The clinical effects, the 6 months and 1 year survival rates，and the toxicity effects were observed, and the clinical effects and survival rates between the 2 groups were compared. Results The observation group had a therapeutic efficiency ratio（TER） of 80.0% which was significantly higher than the control group（50.0%），and the difference was statistically significant（P＜0.05）. The 6 months survival rate and 1 year survival rate were 97.5% and 92.5%, which were both significantly higher than those of control group（87.5% and 77.5%），and all differences were statistically significant（P＜0.05）. The toxicity effects of observation group were lower. Conclusions Preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for NSCLC therapy is effective and safe，which is worthy of study and further application in clinical treatment.. |
| Key words: ［Key words］Thalidomide Gefitinib Neoadjuvant chemotherapy NSCLC |